RESTON, Va.--(BUSINESS WIRE)-- #colocation--TNS has expanded its European exchange footprint by launching services in the Equinix ZH4 colocation data center in Zurich.

OMAHA, Neb. & LONDON--(BUSINESS WIRE)--ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, and leading U.K. convenience retailer Co-op have announced an extension of their strategic technology partnership. The agreement will see Co-op continue to use the full range of solutions offered by ACI's Payments Orchestration Platform, including in-store, online and mobile payment processing as well as end-to-end payments and fraud management. Co-op operates around 2400 sto.

DIVERSIFIED ENERGY COMPANY PLC ("Diversified", or the "Company") Transaction in Own Shares Diversified Energy Company PLC (LSE: DEC) (NYSE: DEC) announces that, in accordance with the terms of its share buyback program announced on 20 March 2025, the Company has purchased 37,142 Ordinary Shares of 20 pence each in the capital of the Company (the "Shares") in the market at a volume weighted average price of 1,008.37 pence per Share through Peel Hunt LLP ("Peel Hunt"). The Shares acquired will, in due course, be cancelled.

VICI Properties offers strong and stable cash flow due to its 100% triple net leases, high-quality tenants, and long average lease terms (41 years), with 100% rent collection in 2020. VICI's leases provide inflation protection with CPI-linked rent escalations set to reach 90% by 2035. The recent earnings miss was due to an accounting adjustment, not a cash flow issue.

Insight with Haslinda Amin, a daily news program featuring in-depth, high-profile interviews and analysis to give viewers the complete picture on the stories that matter. The show features prominent leaders spanning the worlds of business, finance, politics and culture.

Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON's net sales.

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes …

Upgrading TSMC to 'Strong Buy' with a fair value of USD$246 per share due to its leading 2nm technology and market recovery potential. TSMC's 2nm production yields reached 60%, with Apple likely to be the first customer, maintaining a first-move advantage over Intel. TSMC's AI business is expected to grow by 100% year-over-year, contributing significantly to its revenue growth in FY25.

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the “Fear” zone on Monday.

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

TOKYO--(BUSINESS WIRE)--KKR Enters into MoU with Founding Family of FUJI SOFT; to Acquire 100% of FUJI SOFT.

'CyberGuy' Kurt Knutsson discusses 23andMe filing for bankruptcy protection and DNA privacy concerns on 'The Bottom Line.' #foxbusiness #thebottomline #dna #bankruptcy

Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.25-0140 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MS Tolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS Paris, March 25, 2025. The US Food and Drug …

The iShares U.S. Home Construction ETF presents a strong buying opportunity, as the housing market shows signs of recovery with improving supply and declining mortgage rates. Homebuilding companies have outperformed expectations, indicating robust growth potential for ITB, especially with anticipated rate cuts and economic recovery in the second half of the year. While ITB carries macroeconomic risks and higher volatility, it offers diversified exposure to the home construction industry, making it a compelling investment for those seeking growth.

International Game Technology's strategic shift to focus on its core lottery business, divesting digital operations, significantly reduces debt and enhances shareholder value. The company's lottery management model guarantees long-term contracts, providing stability and consistent cash flow, positioning it as a market leader. Despite a slight decline in overall sales, lottery revenues remain strong, with growth in iLottery and international markets, particularly Italy.

PAR Technology Corporation's transition to a subscription-based model and strategic acquisitions drive significant growth, with annual recurring revenue up 102% year-over-year. Key acquisitions like Delaget and TASK Group enhance PAR's capabilities in customer engagement, data analytics, and international expansion, broadening its market reach. Despite margin pressures and customer concentration risks, PAR's strong revenue growth and expanding partnerships, like with Burger King, support a positive long-term outlook.

In 2024's worst home sales since 1995, UWM smashed records with $96B in purchase loans while doubling its refinance market share to 12%. With a $3.5B profit precedent at 6%, UWM is primed for a $260B refinance origination surge if rates drop, capitalizing on future macroeconomic shifts. Despite a 92% Ishbia family-owned float fueling volatility and short-seller noise, UWM's $2.5B cash pile and committed dividend policy offers investors a great buying opportunity.

I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.